KAUAX
Price
$6.44
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
PMAQX
Price
$48.46
Change
+$0.16 (+0.33%)
Updated
Nov 13 closing price
Ad is loading...

KAUAX vs PMAQX

Header iconKAUAX vs PMAQX Comparison
Open Charts KAUAX vs PMAQXBanner chart's image
Federated Hermes Kaufmann A
Price$6.44
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Principal MidCap R6
Price$48.46
Change+$0.16 (+0.33%)
VolumeN/A
CapitalizationN/A
KAUAX vs PMAQX Comparison Chart
Loading...
View a ticker or compare two or three
VS
KAUAX vs. PMAQX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KAUAX is a Buy and PMAQX is a Buy.

FUNDAMENTALS
Fundamentals
PMAQX has more cash in the bank: 29.8B vs. KAUAX (5.33B). PMAQX pays higher dividends than KAUAX: PMAQX (0.10) vs KAUAX (0.00). KAUAX was incepted earlier than PMAQX: KAUAX (24 years) vs PMAQX (8 years). KAUAX is a more actively managed with annual turnover of: 57.00 vs. PMAQX (10.10). PMAQX has a lower initial minimum investment than KAUAX: PMAQX (0) vs KAUAX (1500). PMAQX (32.12) and KAUAX (31.97) have marching annual gain over last year. PMAQX return over 5 years is better than : 55.10 vs. KAUAX (0.62).
KAUAXPMAQXKAUAX / PMAQX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years8 years-
Gain YTD22.66726.39586%
Front LoadN/AN/A-
Min. Initial Investment15000-
Min. Initial Investment IRAN/AN/A-
Net Assets5.33B29.8B18%
Annual Yield % from dividends0.000.10-
Returns for 1 year31.9732.12100%
Returns for 3 years-18.176.88-264%
Returns for 5 years0.6255.101%
Returns for 10 years-2.72N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIXT1.65-0.03
-1.79%
Lixte Biotechnology Holdings
ATRO16.49-0.38
-2.25%
Astronics Corp
LFST7.22-0.18
-2.43%
LifeStance Health Group
CVNA239.98-6.77
-2.74%
Carvana Co
IPSC1.33-0.08
-5.67%
Century Therapeutics